Susan Meier

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event

Carolyn S.P. Lam, Anna Giczewska, Karen Sliwa et al. · JAMA Cardiology · 2020 · 82 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial

Peter B. Berger, K. W. Mahaffey, Susan Meier et al. · American Heart Journal · 2002 · 42 citations

Medicine, Cardiology, Pharmacotherapy +17

A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial

Wayne Batchelor, Kenneth W. Mahaffey, Peter B. Berger et al. · Journal of the American College of Cardiology · 2001 · 41 citations

Medicine, Cardiology, Cardiovascular Pharmacotherapy +14

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler et al. · The Lancet · 2025 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17